Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pdmFlu vaccine for pandemic influenza prevention
NCT06179446Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2023
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07985819 in influenza, sponsored by Pfizer. Primary endpoints: Percentage of participants reporting local reactions at 7 days, Percentage of participants reporting systemic events at 7 days and 5 more. Started Dec 2023; status: completed.
02
Drugs
PF-07985819
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06179446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179446.